Clinical Trial Update: Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ASN-002 with a Hedgehog pathway inhibitor in basal cell carcinoma and basal cell nevus syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma
• Basal Cell Nevus Syndrome

Drugs mentioned

• ASN-002

Snippet

Sponsor: Ascend Biopharmaceuticals Ltd | Conditions: Basal Cell Carcinoma, Basal Cell Nevus Syndrome | Phase 2 | Status: COMPLETED